secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002686
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira reports $147.4M cash, completes LIFT-AD enrollment, CMO Moebius retiring
-------------------------------------------------------------------------------

- Preliminary cash, cash equivalents, and investments of ~$147.4M as of Dec 31, 2023.
- Completed enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for Alzheimer's; topline data expected H2 2024.
- Plans to initiate first-in-human studies of ATH-1105 for ALS in H1 2024.
- CMO Hans Moebius retired effective Jan 5, 2024; will serve as Senior Scientific Advisor through March 31 transition period.
- Over 60 patients continue fosgonimeton treatment beyond 18 months in open-label extension.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/0000950170-24-002686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024002686/atha-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer